What is Verrica Pharmaceuticals Inc.'s market cap?

Verrica Pharmaceuticals Inc. (VRCA) has a market capitalization of $112.2M and trades on NASDAQ.

Who are Verrica Pharmaceuticals Inc.'s competitors?

Verrica Pharmaceuticals Inc.'s key competitors include Vyome Holdings, Inc. Common Stock, Palvella Therapeutics, Inc. Common Stock, Arcutis Biotherapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Verrica Pharmaceuticals Inc. partner with?

Verrica Pharmaceuticals Inc.'s notable partners include Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd..

Where is Verrica Pharmaceuticals Inc. headquartered?

Verrica Pharmaceuticals Inc. is headquartered in United States of America and employs approximately 100 people. It has been publicly traded since 2018.

Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals is a commercial-stage biotechnology company focused on developing and commercializing clinician-administered therapies for dermatologic diseases and skin cancers.

Market cap

$112.18M+39.0%

Table of contents

Earnings

Q1 2026 report

May 12, 2026

Revenue$5.0MBeat by $508.8K EPS-$0.41Beat by $0.18

Read the full report

Next report

Aug 11, 2026 (in a month)

Revenue estimate$5.9M

EPS estimate-$0.40

Competitors

By market cap

Krystal Biotech, Inc.$10.9B+171%

Arcutis Biotherapeutics, Inc.$3.6B+126%

PVL

Palvella Therapeutics$2.2B+687%

Theravance Biopharma$880.0M+55.6%

Verrica Pharmaceuticals Inc.$112.2M+46.1%

Fortress Biotech$109.3M+93.5%

HIN

Vyome Holdings, Inc.$15.7M—

Sonoma Pharmaceuticals, Inc.$6.0M+16.5%

By revenue growth

Arcutis Biotherapeutics, Inc.+95.3%

Theravance Biopharma+68.2%

Krystal Biotech, Inc.+25.2%

By net margin

Theravance Biopharma104.34%+194pp

PVL

Palvella Therapeutics71.68%—

Krystal Biotech, Inc.53.92%+16.7pp

Arcutis Biotherapeutics, Inc.-13.94%+55.0pp

Profile

Verrica Pharmaceuticals is a commercial-stage biotechnology company focused on developing and commercializing clinician-administered therapies for dermatologic diseases and skin cancers. The company's core value proposition centers on its proprietary drug-device combination technology, which delivers standardized formulations of cantharidin to treat highly contagious or refractory skin conditions.

Competitive position

Verrica holds a first-mover advantage with the first FDA-approved treatment for molluscum contagiosum and maintains regulatory exclusivity through NCE status and Orange Book listings.

GeographiesUnited States, Japan, European Union

Customer segmentsMedical specialists, Healthcare providers, Insurance payors

Business modelR&D-based drug development, Direct sales, Licensing and royalties

SuppliersGMP-controlled cantharidin suppliers, Contract manufacturing organizations, Device component manufacturers

CustomersSpecialty pharmacies, Retail independent pharmacies, Physician offices, Managed care organizations

CountryUnited States of America

Listed2018

Employees100.0

CEOJayson Rieger

SectorHealthcare

IndustryBiotechnology

Websiteverrica.com

FilingsSEC EDGAR

Questions, answered.

What is Verrica Pharmaceuticals Inc.'s market cap?: Verrica Pharmaceuticals Inc. (VRCA) has a market capitalization of $112.2M and trades on NASDAQ.
Who are Verrica Pharmaceuticals Inc.'s competitors?: Verrica Pharmaceuticals Inc.'s key competitors include Vyome Holdings, Inc. Common Stock, Palvella Therapeutics, Inc. Common Stock, Arcutis Biotherapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Verrica Pharmaceuticals Inc. partner with?: Verrica Pharmaceuticals Inc.'s notable partners include Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd..
Where is Verrica Pharmaceuticals Inc. headquartered?: Verrica Pharmaceuticals Inc. is headquartered in United States of America and employs approximately 100 people. It has been publicly traded since 2018.